304 related articles for article (PubMed ID: 28235613)
1. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD.
Luukkonen PK; Zhou Y; Nidhina Haridas PA; Dwivedi OP; Hyötyläinen T; Ali A; Juuti A; Leivonen M; Tukiainen T; Ahonen L; Scott E; Palmer JM; Arola J; Orho-Melander M; Vikman P; Anstee QM; Olkkonen VM; Orešič M; Groop L; Yki-Järvinen H
J Hepatol; 2017 Jul; 67(1):128-136. PubMed ID: 28235613
[TBL] [Abstract][Full Text] [Related]
2. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
[TBL] [Abstract][Full Text] [Related]
3. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans.
Borén J; Adiels M; Björnson E; Matikainen N; Söderlund S; Rämö J; Ståhlman M; Ripatti P; Ripatti S; Palotie A; Mancina RM; Hakkarainen A; Romeo S; Packard CJ; Taskinen MR
JCI Insight; 2020 Dec; 5(24):. PubMed ID: 33170809
[TBL] [Abstract][Full Text] [Related]
4. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.
Dongiovanni P; Petta S; Maglio C; Fracanzani AL; Pipitone R; Mozzi E; Motta BM; Kaminska D; Rametta R; Grimaudo S; Pelusi S; Montalcini T; Alisi A; Maggioni M; Kärjä V; Borén J; Käkelä P; Di Marco V; Xing C; Nobili V; Dallapiccola B; Craxi A; Pihlajamäki J; Fargion S; Sjöström L; Carlsson LM; Romeo S; Valenti L
Hepatology; 2015 Feb; 61(2):506-14. PubMed ID: 25251399
[TBL] [Abstract][Full Text] [Related]
5. Interaction of TM6SF2 E167K and PNPLA3 I148M variants in NAFLD in northeast China.
Xu M; Li Y; Zhang S; Wang X; Shen J; Zhang S
Ann Hepatol; 2019; 18(3):456-460. PubMed ID: 31054977
[TBL] [Abstract][Full Text] [Related]
6. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
7. Perturbation of
Pant A; Chen Y; Kuppa A; Du X; Halligan BD; Speliotes EK
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575933
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.
Li BT; Sun M; Li YF; Wang JQ; Zhou ZM; Song BL; Luo J
PLoS Genet; 2020 Aug; 16(8):e1008955. PubMed ID: 32776921
[TBL] [Abstract][Full Text] [Related]
9. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.
Pirola CJ; Sookoian S
Hepatology; 2015 Dec; 62(6):1742-56. PubMed ID: 26331730
[TBL] [Abstract][Full Text] [Related]
10. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children.
Grandone A; Cozzolino D; Marzuillo P; Cirillo G; Di Sessa A; Ruggiero L; Di Palma MR; Perrone L; Miraglia Del Giudice E
Pediatr Obes; 2016 Apr; 11(2):115-9. PubMed ID: 25893821
[TBL] [Abstract][Full Text] [Related]
11. Mechanism and therapeutic strategy of hepatic
Li ZY; Wu G; Qiu C; Zhou ZJ; Wang YP; Song GH; Xiao C; Zhang X; Deng GL; Wang RT; Yang YL; Wang XL
World J Gastroenterol; 2022 Jul; 28(25):2937-2954. PubMed ID: 35978872
[TBL] [Abstract][Full Text] [Related]
12. Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.
Luukkonen PK; Nick A; Hölttä-Vuori M; Thiele C; Isokuortti E; Lallukka-Brück S; Zhou Y; Hakkarainen A; Lundbom N; Peltonen M; Orho-Melander M; Orešič M; Hyötyläinen T; Hodson L; Ikonen E; Yki-Järvinen H
JCI Insight; 2019 Aug; 4(16):. PubMed ID: 31434800
[TBL] [Abstract][Full Text] [Related]
13. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.
Coppola N; Rosa Z; Cirillo G; Stanzione M; Macera M; Boemio A; Grandone A; Pisaturo M; Marrone A; Adinolfi LE; Sagnelli E; Miraglia del Giudice E
Liver Int; 2015 Aug; 35(8):1959-63. PubMed ID: 25581573
[TBL] [Abstract][Full Text] [Related]
14. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
15. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.
Eslam M; Mangia A; Berg T; Chan HL; Irving WL; Dore GJ; Abate ML; Bugianesi E; Adams LA; Najim MA; Miele L; Weltman M; Mollison L; Cheng W; Riordan S; Fischer J; Romero-Gomez M; Spengler U; Nattermann J; Rahme A; Sheridan D; Booth DR; McLeod D; Powell E; Liddle C; Douglas MW; van der Poorten D; George J;
Hepatology; 2016 Jul; 64(1):34-46. PubMed ID: 26822232
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
17. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.
Smagris E; Gilyard S; BasuRay S; Cohen JC; Hobbs HH
J Biol Chem; 2016 May; 291(20):10659-76. PubMed ID: 27013658
[TBL] [Abstract][Full Text] [Related]
19. Depletion of TM6SF2 disturbs membrane lipid composition and dynamics in HuH7 hepatoma cells.
Ruhanen H; Nidhina Haridas PA; Eskelinen EL; Eriksson O; Olkkonen VM; Käkelä R
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Jul; 1862(7):676-685. PubMed ID: 28434889
[TBL] [Abstract][Full Text] [Related]
20. Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.
Newberry EP; Hall Z; Xie Y; Molitor EA; Bayguinov PO; Strout GW; Fitzpatrick JAJ; Brunt EM; Griffin JL; Davidson NO
Hepatology; 2021 Sep; 74(3):1203-1219. PubMed ID: 33638902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
